Cargando…

The use of real-world evidence in ICER’s scoping process and clinical evidence assessments

BACKGROUND: There has been growing interest in using real-world evidence (RWE) for health technology assessment (HTA) in the United States. The Institute for Clinical and Economic Review (ICER) is an independent U.S.-based HTA organization that focuses primarily on pharmaceuticals. RWE is used to in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiao, Boshen, Veenstra, David L, Lee, Woojung, Carlson, Josh J, Devine, Beth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391218/ https://www.ncbi.nlm.nih.gov/pubmed/33251999 http://dx.doi.org/10.18553/jmcp.2020.26.12.1590

Ejemplares similares

Use of real-world evidence in economic assessments of pharmaceuticals in the United States
por: Lee, Woojung, et al.
Publicado: (2021)

Real-world evidence for option value in metastatic melanoma
por: Wong, William B, et al.
Publicado: (2021)

The evolution of ICER’s review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER’s reports
por: Ronquest, Naoko A, et al.
Publicado: (2021)

Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies
por: Langley, Paul C
Publicado: (2019)

Evidence for tuning adipocytes ICER levels for obesity care
por: Brajkovic, Saška, et al.
Publicado: (2012)

Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making
por: Chen, Shuxian, et al.
Publicado: (2021)

ICER, ISPOR AND QALYs: Tales of Imaginary Worlds
por: Langley, Paul C
Publicado: (2019)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2018)

ICER publishes draft scoping report on COVID-19 treatments
Publicado: (2021)

HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales
por: Thokala, Praveen, et al.
Publicado: (2020)

More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
por: Langley, Paul C
Publicado: (2020)

Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications
por: Wex, Jaro, et al.
Publicado: (2023)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

ICER's timelines for assessments extended due to COVID-19
Publicado: (2020)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates
por: Breslau, Rachel Milstein, et al.
Publicado: (2022)

Real world evidence in involuntary psychiatric hospitalizations: 64,685 cases
por: Fornazari, Christina, et al.
Publicado: (2022)

Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy
por: Langley, Paul C
Publicado: (2019)

Nonsense on Stilts – Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds
por: Langley, Paul C
Publicado: (2020)

Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform
por: Bourla, Ariel B., et al.
Publicado: (2021)

ICER is requisite for Th17 differentiation
por: Yoshida, Nobuya, et al.
Publicado: (2016)

The ICER review is in: hope amidst uncertainty
por: Begolka, Wendy Smith, et al.
Publicado: (2022)

The FDA MyStudies app: a reusable platform for distributed clinical trials and real-world evidence studies
por: Wyner, Zachary, et al.
Publicado: (2020)

For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports
por: Shafrin, Jason, et al.
Publicado: (2021)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of Fundamental Measurement
por: Langley, Paul C
Publicado: (2020)

Transportation: De-icers Add Sweet to Salt
por: Tenenbaum, David
Publicado: (2008)

Examining the Use of Real‐World Evidence in the Regulatory Process
por: Beaulieu‐Jones, Brett K., et al.
Publicado: (2019)

4505 Implementation of Real-World Data and Real-World Evidence in Clinical Studies
por: Pham, Jessica, et al.
Publicado: (2020)

Worldwide HTA access to ICER's cost-effectiveness models
Publicado: (2020)

ICER update to pricing models of remdesivir for COVID-19
Publicado: (2020)

Automating Electronic Clinical Data Capture for Quality Improvement and Research: The CERTAIN Validation Project of Real World Evidence
por: Devine, Emily Beth, et al.
Publicado: (2018)

Real-World Evidence for Equality
por: Johnson, C. Erwin, et al.
Publicado: (2021)

The inclusion of real world evidence in clinical development planning
por: Martina, Reynaldo, et al.
Publicado: (2018)

Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience
por: Chougule, Anuradha, et al.
Publicado: (2023)

Inducible cAMP Early Repressor (ICER) and Brain Functions
por: Borlikova, Gilyana, et al.
Publicado: (2009)

ICER releases pricing models for potential COVID-19 treatments
Publicado: (2020)

ICER's second update to pricing models of remdesivir for COVID-19
Publicado: (2020)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rv5p5mkrugh2qcqpgirehr0a23